Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:06:11.012Z.
Consensus retrieved: 2026-10-06T10:16:07.465Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:06:11.012Z.
Quote observation: 2026-10-06T15:03:32.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 229c147a2ba9d4fbfefc05323e2d57c6ed14253bad65a9689088f048178f52a4
Forward PE Ratio (N/A) = Dated Quote Price ($3.40) / Consensus Forward EPS ($-5.85)
FORWARD PE RATIO
N/A
CollPlant Biotechnologies Ltd.
Market Cap
$4.41M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| CollPlant Biotechnologies Ltd. (CLGN) | $4.41M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.57M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.70M | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.73M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.79M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $4.03M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.89M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $3.40, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.85 | $-5.85 – $-5.85 | 1 | n/m |
| 2027-12-31 | $-1.80 | $-1.80 – $-1.80 | 1 | n/m |
| 2028-12-31 | $-1.68 | $-1.68 – $-1.68 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
